R. Fidanza

Patients’ demographic and socioeconomic characteristics influence the therapeutic decision-making process in psoriasis

G. Argenziano, G. Fabbrocini, M. Megna, 2020, PloS one.

Frequency of melanocytic nevi in psoriatic patients is related to treatment and not to disease severity.

S. Chimenti, K. Peris, M. Suppa, 2013, Journal of the American Academy of Dermatology.

Safety and efficacy of certolizumab pegol in a real-life cohort of patients with psoriasis and psoriatic arthritis

R. Giacomelli, F. Carubbi, P. Cipriani, 2019, The Journal of dermatological treatment.

Real‐world evidence of biologic treatments in moderate–severe psoriasis in Italy: Results of the CANOVA (EffeCtiveness of biologic treAtmeNts for plaque psOriasis in Italy: An obserVAtional longitudinal study of real‐life clinical practice) study

G. Argenziano, G. Fabbrocini, M. Megna, 2021, Dermatologic therapy.

Ixekizumab improves disease severity, clinical symptoms and quality of life in patients with genital psoriasis: A 24‐week real‐life experience

M. Esposito, M. Fargnoli, M. Palmieri, 2021, Dermatologic therapy.

Management of biological therapies for chronic plaque psoriasis during COVID‐19 emergency in Italy

I. Zalaudek, G. Argenziano, G. Fabbrocini, 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.

Certolizumab for the treatment of psoriasis and psoriatic arthritis: a real‐world multicentre Italian study

M. Megna, A. Balato, P. Gisondi, 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.

A real-world economic analysis of biologic therapies for moderate-to-severe plaque psoriasis in Italy: results of the CANOVA observational longitudinal study

G. Argenziano, G. Fabbrocini, M. Megna, 2021, BMC Health Services Research.

Vascular patterns in basal cell carcinoma

K. Peris, M. Fargnoli, K Peris, 2011, Journal of the European Academy of Dermatology and Venereology : JEADV.